Reid, Mary E., PhD

Dr. Mary E. Reid joined the staff of Roswell Park Cancer Institute (RPCI) in 2002 as a Research Scientist in the Department of Epidemiology. She came to RPCI from the Arizona Cancer Center, Tucson, AZ, where she served as an Assistant Professor in the Division of Epidemiology and Biostatistics, College of Public Health and Co-Director of the Cancer Prevention and Control Training Program. She completed her doctoral training in Epidemiology and Cancer in 1998 at the University of Arizona, Tucson.

Dr. Reid’s research interests focus on the early detection and chemoprevention of lung and head and neck cancers, and the evaluation of genetic/epigenetic biomarkers of early lesions in high risk populations. Dr. Reid is active in steering the High Risk Lung Cancer Screening Clinic at Roswell, where high risk patients are screened with CT and a bronchoscopy that combines standard white light with autofluorescent imaging. She has experience with chemoprevention trials including wheat bran fiber, selenium. Currently, she directs two ongoing trials in lung cancer prevention at Roswell Park. One ongoing trial is testing a form of Vitamin D. Dr. Reid, in collaboration with Candace Johnson, PhD and Donald L. Trump, MD, has obtained NCI funding to conduct a phase I toxicity study and a randomized, placebo controlled phase II clinical trial to supplement high risk current and former smokers with confirmed premalignant lesions of the lung. In addition, Dr. Reid and Alex Adjei, MD, PhD, have received funding to use low doses of a therapeutic agent, erlotinib, in aerodigestive cancer survivors who are found to have premalignant lesions on screening. The patients will be given progressively lower doses of this agent to assess the effectiveness of treatment on genetic markers in the lung and to assess the level of toxicity at these low doses.

The work on high risk lung cancer screening has led to the formation of an international registry of premalignant lesions of the lung across 14 major institutions in the US, Canada, and Europe. The goal of the registry is to track the natural history of premalignancy of the lung and to determine the role of these lesions in quantifying the risk of lung cancer development. In collaboration with Dr. Adjei (MTET), this effort is supported by a $1,000,000 named philanthropic effort and Institute developmental funds. In addition to the main goal of the registry, these collaborations are expected to yield numerous future research opportunities and information on the genetic and epigenetic factors that influence progression to lung cancer.

Dr. Reid is also heading an effort with the Dental and Head and Neck clinical team to screen high risk head and neck cancer patients with conventional white light and autofluorescent imaging. These screening efforts have led to the start of a chemoprevention trial using a soy extract oral wash.

Dr. Reid is a member of the American Association for Cancer Research (AACR) and the American Society for Preventive Oncology (ASPO). She has authored or co-authored more than 50 publications, serves as a regular reviewer for several cancer, nutrition and epidemiology journals and as a regular reviewer on an NCI Subcommittee J-Educational study section.

Key Publications

• Alberts DS, Martinez ME, Roe DJ, Guillen-Rodriguez J, Marshall JR, van Leeuwen B, Reid ME, Ritenbaugh C, Parish D, Koonce K, Fales L, Vargas P, Bhattacharyya A, Earnest DL, Sampliner R. The Effect of High Fiber Cereal Supplement on Colorectal Adenoma Recurrence: the Wheat Bran Fiber Study. NEJM 2000; 342:1156-62.
• Reid ME, Lillico AJ, Garland L, Turnbull BW, Clark LC, Marshall JR. Lung cancer incidence and selenium supplementation: an update of a clinical trial. CEBP, 11(11): 1285-1291, 2002.
• Moysich KB, Menezes RJ, Ronsani A, Swede H, Reid ME, Cummings KM, Falkner KL, Loewen GM and Bepler G. Regular Aspirin Use and Lung Cancer Risk. BMC Cancer, 2:31, 2002.
• Lillico A, Dalkin BL, Reid ME, Turnbull BW, Slate EH, Combs GF, Marshall JR, Clark LC. Selenium supplementation, baseline plasma selenium status, and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU, 91: 608-612, 2002.
• Lillico AJ, Slate E, Reid ME, Turnbull BW, Wilkins PA, Combs GF, Park HK, Gross EG, Graham GF, Stratton MS, Marshall JR, Clark LC. Selenium Supplementation and the Secondary Prevention of Non-Melanoma Skin Cancer in a Randomized Trial. JNCI, 95(19): 1477-81, 2003.
• Reid ME, Marshall JR, Roe D, Lebowitz M, Alberts DS, Battacharyya AK, Martinez ME Smoking Exposure as a Risk Factor for Prevalent and Recurrent Colorectal Adenomas. CEBP, 12: 1006-1011, 2003.
• Swede H, Dong Y, Reid ME, Marshall JR, Ip C. Cell Cycle Arrest Biomarkers in Human Lung Cancer Cells After Treatment with Selenium in Culture. CEBP, 12: 1248-1252, 2003.
• Jacobs ET, Jiang R, Alberts DS, Greenberg ER, Gunter EW, Karagas MR, Lanza E, Ratnasinghe L, Reid ME, Shatzkin A, Smith-Warner SA, Wallace K, Martinez ME. Selenium and Colorectal Adenoma: Results of a Pooled Analysis, JNCI, 96: 1669-75, 2004.
• Baker JA, McCann SE, Reid ME, Nowell S, Beehler GP, and Moysich KB. Associations between black tea and coffee consumption and risk of lung cancer among smokers. Nutrition and Cancer, 52 (1), 15-21, 2005.
• Jayaprakash V, Menezes RJ, Javle MM, McCann SE, Baker JA, Reid ME, Natarajan N, Moysich KB. Regular aspirin use and esophageal cancer risk. Int J Cancer, 119(1):202-7, 2006.
• Jayaprakash V, Rigual N, Moysich KB, Loree T, Sullivan Nasca M, Menezes RJ, Reid ME. Chemoprevention of Head and Neck Cancer with Aspirin: A Case-Control Study. Arch of Otolaryngology, 132:1231-1236, 2006.
• Ramnath N, Menezes RJ, Loewen G, Dua P, Eid F, Alkhaddo J, Paganelli G, Natarajan N, Reid ME. Hormone Replacement Therapy as a Risk Factor for Non-Small Cell Lung Cancer: Results of a Case Control Study. Oncology, 73(5-6): 305-10, 2008.
• Menezes RJ, Cheney RT, Husain A, Tretiakova M, Loewen G, Johnson CS, Jayaprakash V, Moysich KB, Salgia R, Reid ME. Vitamin D receptor expression in normal, premalignant and malignant human lung tissue. CEBP, 17(5): 1104-10, 2008.
• Reid ME, Santella R, Ambrosone C. Molecular Epidemiology to Better Predict Lung Cancer Risk. Clinical Lung Cancer, 9(3): 149-153, 2008.